NKE — NIKE, Inc.

The market turned decisively negative on October 1, 2026, when Nike reported Q1 FY27 (period ended 2026-08-31): EPS beat at $0.48, but revenue fell 4% YoY to $11.2B and missed, Greater China sales dropped 22% (26% in constant currency) to $1.18B, Converse fell 28% to $263M, and Nike Direct fell 8% with digital down 13%. Management then guided FY27 revenue to decline by a high-single-digit percentage and announced the 'Pace' restructuring (~$2.5B of cumulative savings by FY2031 against ~$1B of charges). Shares fell 7-10% on the print; as of 2026-10-04 the stock sat at $33.87 with RSI(14) at 28.21 after a -23.2% three-month and -11.4% one-month slide. The sell side followed: JPMorgan cut to $33 (Underweight), Wells Fargo to $30 (Equal-Weight), and RBC/Deutsche Bank/Evercore repriced into the $30-$40 range, leaving a nominal 'Buy' consensus but a Hold-skewed 1/33/31/8/0 recommendation distribution.

Revenue peaked at $13.39B in the quarter ended 2023-11-30 and has never reclaimed it: it fell sharply through FY25 (-12.0% YoY in the May 2025 quarter), appeared to stabilize in FY26 (+0.6% Nov 2025, +0.1% Feb 2026, -1.1% May 2026), then re-accelerated downward to -4.3% YoY in the August 2026 quarter, with management guiding FY27 revenue down high-single-digits. Operating margin is the deeper problem: it ran 13.6% (Nov 2023), 12.3% (May 2024) and 11.2% (Nov 2024) but has since printed 7.9%, 4.9%, 8.1%, 12.0% and 7.9% (TTM 8.2%) — roughly 400bps of structural compression, consistent with the wholesale/DTC mix reversal, heavy markdowns and China weakness rather than a one-quarter blip. Diluted EPS has fallen from $1.03 (Nov 2023) to $0.48 (Aug 2026), and free cash flow swung from $2.61B in Nov 2023 to -$64M in the August 2026 quarter on operating cash flow of just $135M. Gross margin has held up better, drifting from ~44.6% to 43.1% TTM, and the balance sheet remains strong. Verdict: the FY26 'stabilization' was a pause, not an inflection — as of October 2026 the trend is deteriorating again.

Optically cheap, actually full. As of 2026-10-04 the trailing P/E was 16.2x (TTM EPS $2.085) and P/S was 1.09x versus a five-year average of 2.68x — hence the 'cheap vs. its own history' label. But the $2.085 TTM EPS still contains better quarters that are rolling off; on the FY27 consensus EPS of $1.366, the forward P/E is ~24.8x, expensive for a company guiding high-single-digit revenue declines. PEG is 2.26x (earnings are shrinking, not growing), P/B is 3.30x, and EV/EBITDA is ~12.4x on depressed EBITDA. The 4.30% dividend yield is a multi-year high, but it is high because the price collapsed, not because the payout grew — roughly $2.2B of annual dividends now roughly equal TTM free cash flow of $2.1B and exceed the net income implied by the FY27 estimate. You are not buying a cheap stock; you are paying roughly a full multiple for a recovery that has not started.

The entire debate is whether $33.87 already discounts the trough. Recovery math: if FY28 EPS recovers to ~$1.90-$2.20 (Pace savings land, China stabilizes, wholesale mix normalizes) and the market pays 18-20x, that is $34-$44. Continued-decline math: another down year at $1.10-$1.20 EPS on 15x is $17-$18. So the shares are priced roughly at fair value for the recovery case with real downside if the decline extends — the asymmetry currently points the wrong way. The tell to watch is the December 17, 2026 print: Nike needs to show the revenue decline decelerating from -4% toward flat and Greater China improving from -22% before estimates stop being cut. Until estimates bottom, price can keep making new lows even while it looks statistically cheap.

Oversold inside a clear downtrend — a mix that has meant more pain rather than an immediate bounce in this name. As of 2026-10-04, RSI(14) was 28.21, with price 6.54% below the 20-day SMA, 13.04% below the 50-day and 30.47% below the 200-day, all three averages stacked above the price. Returns were -5.26% (1 week), -11.43% (1 month), -23.18% (3 months) and -23.35% (6 months) — the decline accelerated into the earnings print. Within a 52-week range of $31.97-$72.39, the stock sits ~6% off its low. Entry-timing implication: risk/reward only improves on evidence of a base — an RSI reclaim of 40-50, a higher low above $31.97, or a positive fundamental catalyst. Buying purely because RSI is under 30 has been a losing trade here for six months.

• China discretionary weakness: Greater China revenue fell 22% YoY (-26% constant currency) to $1.18B in Q1 FY27 — the largest single drag, and a consumer-confidence issue as much as a Nike issue.
• Tariffs and trade policy: potential tariff shifts raise landed costs across a global footwear/apparel supply chain, squeezing a gross margin that has already slipped from ~44.6% to 43.1%.
• Discretionary spending pressure abroad, but unevenly: peers such as On Holding and Lululemon are still growing faster, so a large part of Nike's weakness is company-specific rather than sector-wide.
• FX translation: constant-currency declines were worse than reported in key markets (China -26% cc vs -22% reported), so dollar-reported stabilization can mask real local erosion.
• Channel mix reversal: rebuilding wholesale means a structurally lower-margin revenue mix than the DTC model Nike spent five years building — Nike Direct -8%, digital -13% in Q1 FY27.

• Q2 FY27 earnings on 2026-12-17 (estimated) — the first read on whether the high-single-digit FY27 revenue decline is tracking better or worse and whether China slows its bleed.
• 'Pace' restructuring execution: ~$2.5B of cumulative savings targeted by FY2031 against ~$1B of total charges; early cost-out proof points would be a tangible positive.
• Product/innovation cycle — high-profile athlete-backed launches (e.g., a Caitlin Clark signature shoe) aimed at reviving basketball and lifestyle demand.
• Wholesale partner restocking: North American wholesale was the relative bright spot in Q1 FY27, and continued recovery there would offset DTC weakness.
• Capital return policy: with TTM FCF of $2.1B and dividends near $2.2B, any decision to protect, cut or raise the dividend is now a live stock-moving event.
• Contrarian valuation upgrades — some firms (e.g., Freedom Broker) have moved to Buy on long-term turnaround value.

• China keeps deteriorating — a 22% YoY decline with no visible floor; further erosion spreads to other regions and invalidates the recovery math.
• Converse (-28% to $263M) looks close to broken, and no turnaround plan has been disclosed.
• Dividend coverage risk: a 4.30% yield implies ~$2.2B of payouts against TTM FCF of $2.1B and FY27E EPS of $1.366 — the payout exceeds 150% of guided FY27 earnings and puts the multi-decade dividend growth streak in question.
• Cash-flow quality: Q1 FY27 operating cash flow collapsed to $135M and FCF was -$64M; a positive accruals ratio of 1.53% flags net income running slightly ahead of cash generation.
• Structural share loss to On, Hoka, Adidas and Lululemon — this is execution failure, not purely a cyclical downturn, so a simple 'trough' framing may be wrong.
• Margin structure may not fully recover after the wholesale pivot — TTM operating margin of 8.2% versus the 11-13% earned in FY23-FY24.
• Restructuring execution risk and ~$1B of charges landing in FY27-FY28 earnings, compounded by tariff-driven cost inflation.

Not a buy at $33.87 as of 2026-10-04 — this is a 'show me' turnaround, not a value stock. The brand, the $6.9B cash pile (roughly $1.0B net cash) and the 4.30% dividend yield are real supports, but revenue, margins, EPS and free cash flow are all still deteriorating, the FY27 guide is explicitly negative, and the ~24.8x forward P/E on trough EPS means you are paying full price for a recovery management has not yet demonstrated. The trailing 16.2x P/E and the 'cheap vs. its own history' label are artifacts of lagging EPS. Wait for evidence of a revenue bottom — that is where the asymmetry flips in the buyer's favor.

Normalized mid-cycle earnings power: ~$44.5B of stabilized revenue (versus ~$43.5B FY27E) at a 10% normalized operating margin — between today's 8.2% TTM and the 11-13% of FY23-FY24, reflecting $2.5B of cumulative Pace savings offset by a permanently wholesale-heavier mix — taxed at ~20% on ~1.48B diluted shares, giving about $2.40 of normalized EPS. Applying a 17x justified P/E (well below the 5-year average of 27.7x, appropriate for mid-single-digit normalized growth plus China and competitive uncertainty) yields ~$41, which cross-checks against a ~5% normalized free-cash-flow yield on ~$2.5-2.8B of mid-cycle FCF. That is ~21% above the 2026-10-04 price of $33.87 and modestly above the $38.39 sell-side consensus target.